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The Role of Visfatin in Diabetic Nephropathy
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As a result of the energy overload in obesity, insulin resistance, type 2 diabetes, dyslipi-
demia, hypertension, and atherosclerosis develop, which together comprise the meta-
bolic syndrome. Although the kidney becomes a victim of hyperglycemia in diabetes 
mellitus, recent work has shown that the abnormalities of lipid and glucose metabolism 
in the kidney are similarly important to those in adipose tissue. Interestingly, obesity 
triggers the release of adipokines such as leptin, resistin, and visfatin, and these can 
then be associated with the progression of diabetic nephropathy and other vascular 
complications. These adipokines, which are also synthesized in the kidney, appear to 
have an important role in renal injury associated with insulin resistance. Our studies 
found that visfatin is not only a surrogate marker of systemic inflammation in type 2 
diabetic patients but is also up-regulated in diabetic kidney through the uptake of glu-
cose into renal cells, which leads to the activation of the intracellular insulin signaling 
pathway and pro-inflammatory mechanisms. However, we also observed a beneficial 
effect of visfatin administration to type 2 diabetic mice. Visfatin injection improved dia-
betic nephropathy in vivo, in contrast to our previous in vitro study of cultured renal 
mesangial cells. These results suggest the possibility of multiple cross-talk between 
adipose tissue and kidney in the metabolic syndrome, particularly in diabetic 
nephropathy. Further study should be undertaken to understand the role of adipose 
tissue and kidney as major organs in the metabolic syndrome.
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The kidney is a major target organ in the metabolic syn-
drome, such as in diabetes mellitus. Although the kidney 
becomes a victim of hyperglycemia, its central role in glucose 
metabolism and insulin resistance has not been identified. 
However, it was recently considered that the kidney plays 
an important role in glucose metabolism, and there are fre-
quently abnormalities in glucose metabolism in patients 
with chronic kidney disease.
1 There is also considerable 
evidence from animal studies for renal glucose production 
and utilization.
2-4 The roles of the kidney in glucose metabo-
lism and energy homeostasis have recently been discussed 
under the development of new antidiabetic drugs.
5,6
Recent studies have shown that adipose tissue is a highly 
metabolic organ with pleuripotent functions far beyond the 
mere storage of energy. Adipose tissue is now known to be 
an endocrine organ that secretes a large number of bioactive 
proteins, called adipokines, that have essential roles in en-
ergy homeostasis, glucose and lipid metabolism, insulin re-
sistance, inflammation, and atherosclerosis.
7,8 These in-
clude several active molecules released by adipocytes, such 
as leptin, resistin, and adiponectin, as well as cytokines re-
leased by inflammatory cells, such as tumor necrosis factor 
(TNF)-α, interleukin (IL)-6, macrophage/ monocyte che-
moattractant protein (MCP)-1, and interleukin (IL)-1. In-
terestingly, the circulating levels of these adipokines have 
been found to be altered in experimental animals and pa-
tients with chronic kidney disease, which is an indepen-
dent risk factor of cardiovascular mortality. Furthermore, 
their production, secretion, and regulatory actions are not 
limited to adipose tissue, but are described in other organ 
tissues as well. For example, it is now recognized that the 
kidney itself can alter the clearance of adipokines and pro-
duce them.
Among these adipokines, visfatin is a ubiquitous intra-140
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cellular enzyme, also called nicotinamide phosphoribosyl-
transferase (NAMPT)/pre-B cell colony-enhancing factor 
(PBEF)-1. It was originally characterized from lympho-
cytes, and its enzymatic biochemical basis and structure 
have been established.
9-11 NAMPT constitutes a nuclear 
nicotinamide adenine dinucleotide (NAD
+) salvage/recycling 
pathway, which regulates the functions of NAD
+-dependent 
enzymes, such as the protein deacetylase sirtulin (SIRT)- 
1.
12 NAMPT, a unique rate-limiting enzyme encoded by a 
single gene, catalyzes the conversion of nicotinamide (NAM) 
to nicotinamide mononucleotide (NMN), which in turn is 
converted into NAD
+ by nicotinamide mononucleotide ad-
enylyltransferase (NMNAT)-1. NAD
+ is an important sig-
naling molecule and a coenzyme in metabolic processes and 
redox reactions; it is consumed as a donor of ADP-ribose with 
the release of NAM as a byproduct. NAMPT has been proved 
as a critical NAD biosynthetic enzyme that regulates the 
activity of SIRT-1 in mammalian cells.
11 Finally, SIRT-1 
and NAMPT-mediated systemic NAD
+ biosynthesis to-
gether play an important regulatory role in glucose homeo-
stasis, particularly in the glucose-stimulated insulin se-
cretion of pancrease in the pathophysiology of type 2 dia-
betes.
13 The insulin-mimetic effect of NAMPT, referred to 
as visfatin, has recently been studied in obesity and type 
2 diabetes mellitus. In this review, the role of visfatin in dia-
betic nephropathy will be summarized and discussed.
VISFATIN IN DIABETIC NEPHROPATHY
1. The role of visfatin as an adipokine
Visfatin is increased in inflammatory conditions such as 
acute lung injury, sepsis, and rheumatoid arthritis.
14-16 
Thus, it is considered to be a proinflammatory adipokine 
via either a compensatory response or an epiphenomenon. 
Of note, visfatin was recently reported to be expressed al-
most exclusively in visceral adipose tissue rather than sub-
cutaneous adipose tissue. Adipokines, which are secreted 
by adipocyte tissue, have been studied in association with 
insulin resistance and the metabolic syndrome, including 
obesity, glucose intolerance, and dyslipidemia.
However, studies of visfatin in human populations have 
obtained conflicting results. Elevated plasma visfatin levels 
have been reported in patients with type 2 diabetes melli-
tus.
17-20 On the other hand, other investigative results showed 
decreased plasma visfatin levels in patients with type 1 dia-
betes, liver cirrhosis, exercise in type 2 diabetes, and 3rd 
trimester gestational diabetes.
21-25 Elevated visfatin levels 
were also shown in hemodialysis patients
26,27 and a positive 
correlation of visfatin levels with all stages of chronic kid-
ney disease was observed.
28 Yilmaz et al.
29 published that 
visfatin levels were positively associated not only with in-
sulin resistance but also with the degree of albuminuria in 
type 2 diabetic patients. They suggested that the endothe-
lial dysfunction in early diabetic nephropathy is associated 
with altered circulating levels of visfatin. However, in an-
other experimental study, visfatin was shown to activate 
endothelial nitric oxide synthase (eNOS) via Akt and mi-
togen-activated protein (MAP) kinase and MCP-1 and im-
prove endothelial cell function, angiogenesis, and athero-
sclerosis.
30,31 Thus, controversy exists among clinical stud-
ies and experimental data for the role of visfatin in diabetic 
nephropathy. Whether this phenomenon primarily arises 
from direct vascular defects or is secondary to the presence 
of visceral obesity and a deranged metabolic milieu that is 
characteristic of many patients with diabetes remains un-
clear.
Consistent with several reports, we observed that plas-
ma visfatin levels were elevated in patients and animals 
with type 2 diabetic nephropathy.
32,33 Interestingly, in our 
in vitro study,
34 visfatin was synthesized in renal glomeru-
lar mesangial cells, upregulated by high glucose stimula-
tion. In addition, exogenous visfatin stimulation in renal 
cells upregulated the synthesis of profibrotic molecules, in-
cluding transforming growth factor (TGF)-β1, plasminogen 
activator inhibitor (PAI)-1, and type I collagen. Given these 
findings, the pathophysiologic relevance of visfatin seems 
to be as a proinflammatory adipokine regarding type 2 dia-
betes and other metabolic complications.
2. The insulin-mimic effect of visfatin
Despite the insulin-mimic effect of visfatin, controversy 
exists over its role insulin resistance. The exciting paper 
of Fukuhara et al., which had described the insulin-mime-
tic effect of visfatin and its naming, has been finally ret-
racted. Several studies failed to show an association of cir-
culating visfatin with insulin sensitivity.
19,35-37 There has 
been no report of whether the relation between visfatin and 
insulin is synergistic. However, it is still interesting wheth-
er visfatin binds directly to the insulin receptor at a site dis-
tinct from insulin and has hypoglycemic effects by reducing 
glucose release from hepatocytes and stimulating glucose 
utilization in peripheral tissue.
38 Insulin receptor expre-
ssion has been ascertained in renal cells such as proximal 
tubular cells, mesangial cells, and podocytes. However, the 
affinity of visfatin for the insulin receptor and other recep-
tors such as insulin-like growth factor receptor and insulin- 
receptor like receptor is unclear. In fact, insulin also binds 
with low affinity to insulin-like growth factor receptor and 
insulin-receptor like receptor in kidney. A recent study re-
ported that insulin receptor expression was shown to be re-
duced in the kidney of an insulin-resistant rat animal 
model.
39 Despite a high plasma insulin level, decreased in-
sulin receptor expression has been explained to correlate 
with insulin resistance in various tissues such as liver, 
skeletal muscle, and adipose tissue. However, this finding 
in the kidney can be different among renal cells and may 
be distinct depending on the organ type, i.e., whether liver, 
skeletal muscle, or adipose tissue. On the other hand, an-
other study suggested that visfatin does not have insulin- 
mimetic actions but rather has a regulatory role in glucose- 
stimulated insulin secretion in pancreatic β-cells in vitro 
and in vivo.
40 Those authors demonstrated that mice lacking 
visfatin synthesis develop impaired glucose tolerance and 
defective insulin secretion, which are restored by admin-141
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istration of visfatin. Taken together, these results suggest 
that visfatin may act as a multiplayer in either a cell- or 
tissue-dependent manner. 
Interestingly, in our in vitro study,
34 high glucose stimu-
lation upregulated visfatin synthesis and then visfatin sti-
mulated glucose uptake via the glucose transporter (GLUT)-1 
in renal mesangial cells. However, angiotensin ll stimula-
tion did not induce visfatin synthesis. We found that exoge-
nous visfatin stimulation in renal mesangial cells upregu-
lated the insulin signaling pathway and induced synthesis 
of its downstream components of profibrotic molecules.
In contrast, another study published data indicating 
that life span extension in mice is associated with reduced 
insulin receptor signaling cascade, which upregulates the 
expression of SIRT-1 proteins.
41 Therefore, there could be 
possible cross-talk between the visfatin-mediated and in-
sulin signaling pathways via various physiologic mecha-
nisms.
42
3. Visfatin as a nicotinamide adenine dinucleotide (NAD) 
biosynthetic enzyme
Recent studies have shown that disturbances in the circa-
dian clock feedback cycle through NAMPT/visfatin-medi-
ated NAD
+ biosynthesis may cause an imbalance in energy 
metabolism and homeostasis.
13 Other data showed that 
this optimizing of SIRT1-mediated p53 degradation by vis-
fatin induces the extension of human cell life span, such as 
smooth muscle cells, and the resistance to oxidative stress.
43 
If visfatin is impaired in the aging-dependent circadian cy-
cle and this leads to the decline of pancreatic cell function 
in type 2 diabetes, visfatin could be an effective target for 
the treatment and prevention of type 2 diabetes.
Furthermore, a recent study suggested that angiotensin 
ll plays a role in the prolongation of the life span in mice.
44 
Agtr1a-/- mice developed a longevity phenotype and upre-
gulation of visfatin expression in the kidney. Although high 
glucose stimulation induces renal cell visfatin synthesis 
and intracellular glucose transport, which leads to increa-
sed pro-fibrotic molecular expression as demonstrated in 
our previous in vitro study,
34 angiotensin ll did not induce 
visfatin synthesis and mice lacking angiotensin receptor 
expressed visfatin upregulation. Taken together, these da-
ta suggest that visfatin may have multiple actions in the 
kidney, even in the regulation of NAD-consuming enzymes 
such as sirtuins. In fact, we examined the effect of intra-
peritoneal visfatin administration on diabetic nephropathy 
in mice. In our in vivo study, visfatin had a protective effect 
on the albuminuria of diabetic nephropathy in mice (data 
not published). Exogenous visfatin infusion did not show 
a large glucose-lowering effect through glucose uptake into 
renal cells. Besides, the plasma visfatin concentration is 
much lower than the insulin concentration, although the 
affinity of visfatin for the insulin receptor appears to be 
similar to that of insulin.
45 Although high glucose stimu-
lates intrarenal cellular visfatin synthesis, and then glu-
cose taken up by renal cells activates the intracellular sig-
naling pathway leading to injury in diabetic nephropathy, 
plasma visfatin elevated by autocrine action may act via 
a different regulatory pathway. The enzymatic and func-
tional role of visfatin remains unknown in the kidney.
42 
Therefore, visfatin has a compensatory effect via both auto-
crine and paracrine pathways to improve insulin resistance 
and lipid metabolism. Particularly, one study showed that 
long-term visfatin infusion does not decrease the abundance 
of insulin receptors in the kidney of insulin-resistant rats, 
which is different in other tissues, such as liver, skeletal 
muscle, and adipose tissue.
39 It is also possible that a more 
physiologic route of intraperitoneal visfatin injection may 
have benefit compared with vascular infusion, which is di-
rectly accumulated in the liver and visceral adipose tissue, 
which are the main organs regulating lipid and glucose me-
tabolism, before sufficient concentration levels are reached 
in the systemic circulation of plasma, heart, and kidney. 
In addition, an unknown receptor for visfatin may exist, 
which could indirectly affect the insulin signaling pathway. 
For example, the enzymatic regulatory action of NAMPT/ 
visfatin-mediated NAD synthesis might have a major ef-
fect on diabetic nephropathy through a different pathway. 
Nonetheless, it is equally possible that differences in the 
models of insulin resistance studied may have accounted 
for this seeming discrepancy.
CONCLUSION
Controversy remains concerning the pleiotropic roles of 
visfatin, although its enzymatic regulatory functions have 
already been identified with energy metabolism. The inter-
esting point is that visfatin appears to act as a multiplayer 
adipokine in inflammation, obesity, the metabolic syn-
drome, and cardiovascular disease, including diabetic ne-
phropathy. Particularly in humans and animals with type 
2 diabetic nephropathy, the results of several studies sug-
gest that visfatin could be a surrogate marker. On the other 
hand, its direct administration might be beneficial or harm-
ful depending on species, organs, and cell types. There is 
no doubt about its different effects on various diseases. 
Therefore, further studies need to be performed to clarify 
the effects of visfatin on cellular metabolism and physiology, 
ultimately leading to adjustments of therapeutic strategies 
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